| 12.9 -2.7 (-17.31%) | 10-16 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 18.92 |
1-year : | 22.89 |
| Resists | First : | 16.2 |
Second : | 19.6 |
| Pivot price | 15.82 |
|||
| Supports | First : | 10.69 |
Second : | 8.9 |
| MAs | MA(5) : | 14.62 |
MA(20) : | 16.01 |
| MA(100) : | 10.96 |
MA(250) : | 16.74  |
|
| MACD | MACD : | 0.3 |
Signal : | 0.9 |
| %K %D | K(14,3) : | 16.6 |
D(3) : | 17.5 |
| RSI | RSI(14): 42.2 |
|||
| 52-week | High : | 41.72 | Low : | 6.78 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ BNR ] has closed below the lower bollinger band by 2.7%. Bollinger Bands are 8.4% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 15.95 - 16.03 | 16.03 - 16.09 |
| Low: | 12.24 - 12.33 | 12.33 - 12.4 |
| Close: | 12.78 - 12.91 | 12.91 - 13.02 |
Headquartered in Guangzhou, China, and established in 2014, Burning Rock Biotech Limited is primarily engaged in developing and providing diagnostic solutions for cancer therapy selection within the People's Republic of China. Its operations are structured across three key segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company leverages next-generation sequencing (NGS) technology to offer a diverse portfolio of tests designed to guide therapeutic decisions and predict prognoses for a wide array of cancer types. These include, but are not limited to, lung, gastrointestinal, prostate, breast, lymphomas, thyroid, colorectal, ovarian, pancreatic, and bladder cancers. These analyses can be performed on both tissue and liquid biopsy samples. Burning Rock's flagship products encompass OncoCompass IO, a liquid biopsy test; OncoScreen IO, a comprehensive pan-cancer test for tissue samples; OncoCompass Target, a circulating tumor DNA (ctDNA) liquid biopsy-based test specifically for non-small cell lung cancer (NSCLC); ColonCore, which assesses microsatellite instability (MSI) and identifies genetic mutations relevant to gastrointestinal cancers; and the OncoScreen ParpMatch and OncoCompass ParpMatch tests, which target genes critical for homologous recombination deficiency. To further enhance its offerings, the company has entered into strategic agreements, including a development and commercialization license with Myriad Genetics, Inc. for Myriad myChoice tumor testing in China, and a licensing agreement with Oncocyte Corporation for DetermaRx, a risk stratification test for early-stage lung cancer patients, also for the Chinese market. Burning Rock also actively collaborates on clinical trials and research studies with a notable roster of pharmaceutical and biotech partners, such as AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, IMPACT Therapeutics, and Merck KGaA.
Sat, 17 Oct 2026
(BNR) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Sat, 10 Oct 2026
Burning Rock Biotech : OncoCompass Target CDx Kit Enters NMPA Priority Approval Procedure - www.marketscreener.com
Wed, 30 Sep 2026
Burning Rock Biotech Ltd (BNR) Shares Fall 6.9% -- What GF Score of 49 Tells Investors - GuruFocus
Wed, 16 Sep 2026
Precision Trading with Burning Rock Biotech Limited (BNR) Risk Zones - Stock Traders Daily
Sat, 12 Sep 2026
Burning Rock Biotech (BNR) Stock Rallies While Losses Still Deepen - Simply Wall Street
Thu, 10 Sep 2026
Burning Rock Reports Second Quarter 2026 Financial Results - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 9 (M) |
| Shares Float | 3 (M) |
| Held by Insiders | 213.5 (%) |
| Held by Institutions | 47.1 (%) |
| Shares Short | 41 (K) |
| Shares Short P.Month | 38 (K) |
| EPS | -0.81 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 6.82 |
| Profit Margin | -13.6 % |
| Operating Margin | -13.4 % |
| Return on Assets (ttm) | -5.2 % |
| Return on Equity (ttm) | -12.9 % |
| Qtrly Rev. Growth | -9.4 % |
| Gross Profit (p.s.) | 42.36 |
| Sales Per Share | 56.82 |
| EBITDA (p.s.) | -6.62 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -12 (M) |
| Levered Free Cash Flow | 13 (M) |
| PE Ratio | -16.13 |
| PEG Ratio | 0 |
| Price to Book value | 1.88 |
| Price to Sales | 0.22 |
| Price to Cash Flow | -9.31 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|